A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells

Anticancer Drugs. 2008 Feb;19(2):151-8. doi: 10.1097/CAD.0b013e3282f28fe.

Abstract

Peroxisome proliferator-activated receptor (PPAR) gamma agonists are used clinically for treating diabetes mellitus and cancer. 2-Methyl-2[(1-{3-phenyl-7-propylbenzol[d]isoxazol-6-yl}oxy)propyl]-1H-4-indolyl) oxy]propanoic acid (BPR1H0101) is a novel synthetic indole-based compound, discovered through research to identify new PPARgamma agonists, and it acts as a dual agonist for PPARgamma and PPARalpha. Isobologram analysis demonstrated that BPR1H0101 is capable of antagonistic interaction with the topoisomerase (topo) II poison, VP16. A study of its mechanism showed that BPR1H0101 could inhibit the catalytic activity of topo II in vitro, but did not produce detectable topo II-mediated DNA strand breaks in human oral cancer KB cells. Furthermore, BPR1H0101 could inhibit VP16-induced topo II-mediated DNA cleavage and ataxia-telangiectasia-mutated phosphorylation in KB cells. The results suggest that BPR1H0101 can interfere with the topo II reaction by inhibiting catalytic activity before the formation of the intermediate cleavable complex; consequently, it can impede VP16-induced topo II-mediated DNA cleavage and cell death. This is the first identified PPARalpha/gamma agonist that can serve as a topo II catalytic inhibitor, to interfere with VP16-induced cell death. The result might have relevance to the clinical use of the PPARalpha/gamma agonist in combination chemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacology
  • Ataxia Telangiectasia Mutated Proteins
  • Blotting, Western
  • Catalysis / drug effects
  • Cell Cycle Proteins / metabolism
  • Chromans / pharmacology
  • DNA Breaks / drug effects
  • DNA Cleavage / drug effects
  • DNA Topoisomerases, Type II / metabolism
  • DNA, Circular / drug effects
  • DNA-Binding Proteins / metabolism
  • Dose-Response Relationship, Drug
  • Drug Antagonism
  • Etoposide / pharmacology
  • Humans
  • Indoles / chemistry
  • Indoles / pharmacology*
  • KB Cells
  • Molecular Structure
  • Peroxisome Proliferator-Activated Receptors / agonists*
  • Peroxisome Proliferator-Activated Receptors / genetics
  • Peroxisome Proliferator-Activated Receptors / metabolism
  • Phosphorylation / drug effects
  • Propionates / chemistry
  • Propionates / pharmacology*
  • Protein Serine-Threonine Kinases / metabolism
  • RNA, Small Interfering / genetics
  • Thiazolidinediones / pharmacology
  • Topoisomerase II Inhibitors*
  • Transcriptional Activation / drug effects
  • Transfection
  • Troglitazone
  • Tumor Suppressor Proteins / metabolism

Substances

  • 2-methyl-2-((1-(3-phenyl-7-propylbenzo(d)isoxazol-6-yl)oxy)propyl)-1H-4-indolyloxypropanoic acid
  • Antineoplastic Agents, Phytogenic
  • Cell Cycle Proteins
  • Chromans
  • DNA, Circular
  • DNA-Binding Proteins
  • Indoles
  • Peroxisome Proliferator-Activated Receptors
  • Propionates
  • RNA, Small Interfering
  • Thiazolidinediones
  • Topoisomerase II Inhibitors
  • Tumor Suppressor Proteins
  • Etoposide
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • Protein Serine-Threonine Kinases
  • DNA Topoisomerases, Type II
  • Troglitazone